 Blair Fennimore
Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 6 | 2026 | 366 | 1.060 |
Why?
| | Colon | 3 | 2020 | 310 | 0.650 |
Why?
| | Mucoproteins | 1 | 2020 | 8 | 0.650 |
Why?
| | Cholestasis | 2 | 2020 | 217 | 0.650 |
Why?
| | Colitis | 2 | 2020 | 282 | 0.640 |
Why?
| | Gastrointestinal Microbiome | 6 | 2026 | 773 | 0.610 |
Why?
| | Cholangitis, Sclerosing | 1 | 2020 | 61 | 0.610 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 182 | 0.590 |
Why?
| | Bile Acids and Salts | 1 | 2020 | 163 | 0.580 |
Why?
| | Gastrointestinal Diseases | 2 | 2015 | 222 | 0.460 |
Why?
| | Intestinal Pseudo-Obstruction | 1 | 2015 | 8 | 0.460 |
Why?
| | Nausea | 1 | 2015 | 112 | 0.440 |
Why?
| | Myositis | 1 | 2015 | 57 | 0.440 |
Why?
| | Muscle, Smooth | 1 | 2015 | 153 | 0.430 |
Why?
| | Abdominal Pain | 1 | 2015 | 149 | 0.410 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 43 | 0.320 |
Why?
| | Spondylarthritis | 2 | 2021 | 50 | 0.290 |
Why?
| | Homosexuality, Male | 2 | 2026 | 234 | 0.250 |
Why?
| | Intestines | 2 | 2021 | 356 | 0.250 |
Why?
| | Crohn Disease | 2 | 2021 | 262 | 0.250 |
Why?
| | Colonoscopy | 2 | 2024 | 267 | 0.250 |
Why?
| | Prevotella | 1 | 2025 | 31 | 0.220 |
Why?
| | Intestinal Mucosa | 3 | 2019 | 676 | 0.210 |
Why?
| | HIV Infections | 3 | 2026 | 3235 | 0.200 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 92 | 0.190 |
Why?
| | Colonic Polyps | 1 | 2024 | 89 | 0.190 |
Why?
| | Drug Monitoring | 1 | 2026 | 402 | 0.180 |
Why?
| | Disease Susceptibility | 2 | 2021 | 347 | 0.180 |
Why?
| | Patient Acceptance of Health Care | 2 | 2026 | 895 | 0.170 |
Why?
| | Ursodeoxycholic Acid | 1 | 2020 | 17 | 0.160 |
Why?
| | Ustekinumab | 1 | 2020 | 17 | 0.160 |
Why?
| | Dextran Sulfate | 1 | 2020 | 93 | 0.160 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 6 | 0.160 |
Why?
| | Gastrointestinal Agents | 1 | 2020 | 65 | 0.150 |
Why?
| | Metagenomics | 1 | 2021 | 151 | 0.150 |
Why?
| | Antiporters | 1 | 2019 | 22 | 0.150 |
Why?
| | Tryptophan | 1 | 2021 | 183 | 0.150 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 2017 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2024 | 389 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2020 | 1225 | 0.140 |
Why?
| | Acidosis | 1 | 2019 | 107 | 0.140 |
Why?
| | Metabolomics | 2 | 2022 | 737 | 0.140 |
Why?
| | Aldehydes | 1 | 2019 | 140 | 0.140 |
Why?
| | Colitis, Ulcerative | 1 | 2020 | 149 | 0.140 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 17 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 1005 | 0.130 |
Why?
| | Feces | 3 | 2026 | 500 | 0.130 |
Why?
| | Adenoma | 2 | 2024 | 219 | 0.120 |
Why?
| | Mice, Knockout | 2 | 2020 | 3153 | 0.120 |
Why?
| | Biopsy | 2 | 2020 | 1093 | 0.120 |
Why?
| | Liver Diseases | 1 | 2019 | 307 | 0.120 |
Why?
| | Adenosine | 2 | 2019 | 255 | 0.120 |
Why?
| | Antioxidants | 1 | 2019 | 550 | 0.110 |
Why?
| | Sexual and Gender Minorities | 1 | 2020 | 272 | 0.110 |
Why?
| | CD3 Complex | 1 | 2015 | 113 | 0.110 |
Why?
| | Reproduction | 1 | 2016 | 212 | 0.110 |
Why?
| | Mothers | 1 | 2021 | 774 | 0.100 |
Why?
| | Humans | 22 | 2026 | 147306 | 0.100 |
Why?
| | Microbiota | 1 | 2022 | 736 | 0.100 |
Why?
| | Intestine, Small | 1 | 2015 | 168 | 0.100 |
Why?
| | Neutrophils | 1 | 2019 | 1135 | 0.100 |
Why?
| | Lymphocytes | 1 | 2015 | 378 | 0.100 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2013 | 69 | 0.100 |
Why?
| | Radiography | 1 | 2015 | 862 | 0.090 |
Why?
| | Inflammation | 3 | 2019 | 2921 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4605 | 0.090 |
Why?
| | A Kinase Anchor Proteins | 1 | 2013 | 75 | 0.090 |
Why?
| | Oxidative Stress | 1 | 2019 | 1368 | 0.090 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2013 | 300 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1518 | 0.080 |
Why?
| | Cost-Benefit Analysis | 3 | 2020 | 654 | 0.080 |
Why?
| | Colorectal Neoplasms | 2 | 2024 | 877 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 2016 | 607 | 0.080 |
Why?
| | Liver | 1 | 2019 | 1916 | 0.080 |
Why?
| | Adult | 9 | 2026 | 41406 | 0.080 |
Why?
| | Algorithms | 3 | 2026 | 1868 | 0.080 |
Why?
| | Platelet Membrane Glycoproteins | 1 | 2009 | 31 | 0.080 |
Why?
| | Infliximab | 2 | 2020 | 111 | 0.080 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 663 | 0.080 |
Why?
| | Biological Products | 2 | 2026 | 258 | 0.080 |
Why?
| | Gram-Positive Bacteria | 1 | 2009 | 48 | 0.080 |
Why?
| | Mice | 4 | 2020 | 18493 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 633 | 0.070 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2009 | 232 | 0.060 |
Why?
| | Early Detection of Cancer | 1 | 2012 | 506 | 0.060 |
Why?
| | Middle Aged | 7 | 2026 | 36821 | 0.060 |
Why?
| | Up-Regulation | 2 | 2019 | 848 | 0.060 |
Why?
| | Female | 9 | 2026 | 80081 | 0.060 |
Why?
| | Male | 9 | 2026 | 73954 | 0.060 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2026 | 41 | 0.060 |
Why?
| | Animals | 5 | 2020 | 38417 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2012 | 1379 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2026 | 430 | 0.050 |
Why?
| | Hospitalization | 2 | 2026 | 2496 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3660 | 0.040 |
Why?
| | Granzymes | 1 | 2021 | 51 | 0.040 |
Why?
| | Aged | 2 | 2024 | 26516 | 0.040 |
Why?
| | Azathioprine | 1 | 2020 | 44 | 0.040 |
Why?
| | Adalimumab | 1 | 2020 | 54 | 0.040 |
Why?
| | Integrin alpha Chains | 1 | 2020 | 22 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 175 | 0.040 |
Why?
| | Leukocyte Disorders | 1 | 2019 | 9 | 0.040 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 2019 | 25 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 126 | 0.040 |
Why?
| | Prospective Studies | 2 | 2024 | 8166 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 132 | 0.040 |
Why?
| | Models, Economic | 1 | 2020 | 64 | 0.040 |
Why?
| | Receptors, CCR5 | 1 | 2020 | 60 | 0.040 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2019 | 30 | 0.040 |
Why?
| | Colectomy | 1 | 2020 | 107 | 0.040 |
Why?
| | Lactation | 1 | 2021 | 195 | 0.040 |
Why?
| | Immune System Diseases | 1 | 2019 | 40 | 0.040 |
Why?
| | Neutrophil Activation | 1 | 2019 | 84 | 0.040 |
Why?
| | Glutathione Transferase | 1 | 2019 | 92 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 188 | 0.040 |
Why?
| | Lysosomes | 1 | 2019 | 133 | 0.040 |
Why?
| | Milk, Human | 1 | 2021 | 176 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 337 | 0.030 |
Why?
| | Ribosomes | 1 | 2019 | 193 | 0.030 |
Why?
| | Superoxide Dismutase | 1 | 2019 | 308 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1046 | 0.030 |
Why?
| | Antigens, CD | 1 | 2020 | 562 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1912 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 677 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1260 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1845 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2020 | 502 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1077 | 0.030 |
Why?
| | NF-kappa B | 1 | 2019 | 676 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 568 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2026 | 17561 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 840 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1794 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 2017 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 377 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2013 | 249 | 0.020 |
Why?
| | Proteomics | 1 | 2019 | 1205 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4170 | 0.020 |
Why?
| | Caco-2 Cells | 1 | 2009 | 79 | 0.020 |
Why?
| | Health Care Costs | 1 | 2012 | 428 | 0.020 |
Why?
| | Isoenzymes | 1 | 2009 | 296 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 334 | 0.020 |
Why?
| | Biological Transport | 1 | 2009 | 425 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 6042 | 0.020 |
Why?
| | RNA Interference | 1 | 2009 | 477 | 0.020 |
Why?
| | Cell Line | 1 | 2013 | 2832 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2009 | 372 | 0.020 |
Why?
| | Infant | 1 | 2021 | 10195 | 0.010 |
Why?
| | Cell Membrane | 1 | 2009 | 711 | 0.010 |
Why?
| | Signal Transduction | 1 | 2019 | 5272 | 0.010 |
Why?
| | Risk Factors | 1 | 2020 | 11017 | 0.010 |
Why?
| | Pregnancy | 1 | 2016 | 7276 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 14437 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1209 | 0.010 |
Why?
| | Child | 1 | 2022 | 22980 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 22826 | 0.010 |
Why?
|
|
Fennimore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|